Key Takeaways & Executive Findings
- •• ADE is a critical concern in vaccine development, as suboptimal antibody responses can enhance viral infection and disease severity. • Fc receptor-mediated uptake and complement activation are key mechanisms driving ADE in various viral infections. • Understanding ADE mechanisms is essential for designing safe and effective vaccines against emerging viral pathogens. • Novel vaccine strategies, such as targeting non-neutralizing epitopes or using engineered antibodies, may reduce ADE risk.
Abstract
Antibody-dependent enhancement (ADE) of viral infection is a phenomenon where pre-existing antibodies from a previous infection or vaccination enhance the entry and replication of a virus in host cells, leading to increased disease severity. This review explores the molecular mechanisms underlying ADE, including the role of Fc receptors and complement pathways, and discusses its implications for vaccine development and therapeutic strategies. We highlight recent findings on ADE in various viruses, such as dengue, Zika, and coronaviruses, and propose potential approaches to mitigate ADE in vaccine design. Our analysis underscores the need for careful evaluation of antibody responses in vaccine trials to avoid ADE and ensure safety and efficacy.
1. Introduction
Antibody-dependent enhancement (ADE) of viral infection is a phenomenon where pre-existing antibodies from a previous infection or vaccination enhance the entry and replication of a virus in host cells, leading to increased disease severity. This phenomenon has been observed in several viral infections, including dengue, Zika, and coronaviruses, and poses a significant challenge for vaccine development. The underlying mechanisms involve the binding of virus-antibody complexes to Fc receptors on immune cells, facilitating viral entry and replication, as well as the activation of complement pathways that can exacerbate inflammation and tissue damage.
Understanding ADE is crucial for the design of safe and effective vaccines, as suboptimal antibody responses can inadvertently enhance disease. This review aims to provide a comprehensive overview of the molecular mechanisms of ADE, its clinical implications, and potential strategies to mitigate its effects in vaccine development. By synthesizing recent research findings, we hope to inform future vaccine design and therapeutic approaches to prevent ADE-related complications.
Loading authentic research manuscript (Pages 1–5)...
John Doe, Jane Smith, Richard Roe (2026). Antibody-Dependent Enhancement of Viral Infection: Mechanisms and Therapeutic Implications. Chinese Journal of New Drugs. https://doi.org/10.1000/example.2025.001
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is antibody-dependent enhancement (ADE)?
Antibody-dependent enhancement (ADE) is a phenomenon where pre-existing antibodies from a previous infection or vaccination enhance the entry and replication of a virus in host cells, leading to increased disease severity. This occurs when non-neutralizing antibodies bind to the virus and facilitate its uptake into cells via Fc receptors, potentially worsening the infection.
Which viruses are known to cause ADE?
ADE has been observed in several viruses, including dengue virus, Zika virus, respiratory syncytial virus (RSV), and coronaviruses such as SARS-CoV-2. It is particularly well-documented in dengue virus, where secondary infections with different serotypes can lead to severe disease due to ADE.
How does ADE affect vaccine development?
ADE poses a significant challenge in vaccine development because suboptimal antibody responses can enhance viral infection and disease severity. Vaccines that induce non-neutralizing antibodies or waning immunity over time may increase the risk of ADE upon natural infection. Therefore, vaccine candidates must be carefully evaluated to ensure they elicit protective neutralizing antibodies without triggering ADE.
What are the mechanisms behind ADE?
The primary mechanisms of ADE involve the binding of virus-antibody complexes to Fc receptors on immune cells, such as macrophages and dendritic cells, which facilitates viral entry and replication. Additionally, complement activation can exacerbate inflammation and tissue damage. These processes can lead to increased viral load and more severe disease.
Can ADE be prevented in vaccine design?
Yes, ADE can be mitigated through careful vaccine design. Strategies include targeting conserved neutralizing epitopes, avoiding non-neutralizing epitopes, using adjuvants that promote a balanced immune response, and engineering antibodies with modified Fc regions to reduce Fc receptor binding. Additionally, monitoring antibody responses in clinical trials is essential to detect any potential ADE risk.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.